Galcanezumab for the prevention of cluster headache
| Autor: | Luca Giani, Alberto Proietti Cecchini, Massimo Leone |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Pharmacology medicine.medical_specialty business.industry Calcitonin Gene-Related Peptide Migraine Disorders Cluster headache Clinical Biochemistry Antibodies Monoclonal Cluster Headache Antibodies Monoclonal Humanized medicine.disease 03 medical and health sciences Antineoplastic Agents Immunological Treatment Outcome 030104 developmental biology 0302 clinical medicine Tolerability 030220 oncology & carcinogenesis Internal medicine Drug Discovery Humans Medicine business |
| Zdroj: | Expert Opinion on Biological Therapy. 20:1133-1142 |
| ISSN: | 1744-7682 1471-2598 |
| Popis: | Cluster headache (CH) is among the worst painful conditions. The available therapies are scarce and not specific, leaving many patients unsatisfied because of poor efficacy and/or tolerability. Patients not responding to common treatments are offered semi-invasive and invasive procedures with uncertain results. Based on the current understanding of CH pathophysiology, new possible therapeutic approaches come from drugs interfering with Calcitonin Gene Related Peptide (CGRP).After summarizing the evidence for CGRP involvement in CH pathophysiology, we review the published literature (PubMed) and information (clinicaltrials.gov, EudraCT, EMA and FDA websites) regarding a novel anti-CGRP monoclonal antibody, Galcanezumab, its pharmacological properties, development, and evidence for the treatment of CH. Publications regarding other indications (migraine) are considered for completeness and safety/tolerability profile.In one randomized clinical trial, Galcanezumab has proven to be effective and safe as a preventive treatment in episodic CH, with a favorable tolerability profile offering a potential new option in the therapeutic arsenal. Inefficacy of galcanezumab in chronic CH as well as the inefficacy of another monoclonal antibody against CGRP (fremanezumab) in both episodic and chronic CH question the scalability of the drug in CH management. Further, studies comparing galcanezumab to the current standard treatments are highly desirable. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|